UOC
BMRN icon

UBS O'Connor’s BioMarin Pharmaceuticals BMRN Stock Holding History

UBS O'Connor’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$4.13K – 449
2024
Q3 		$4.13K Sell
15,000
-25,000
-63% -$2.09M ﹤0.01% 486
2024
Q2 		$33K Buy
40,000
+15,000
+60% +$1.25M ﹤0.01% 464
2024
Q1 		$6.25K Sell
25,000
-18,000
-42% -$1.61M ﹤0.01% 495
2023
Q4 		$31.2K Buy
+43,000
New +$3.8M ﹤0.01% 432

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS O'Connor's BMRN Position: Q2 2025 in Review

UBS O'Connor sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 5,258 shares — an estimated $372K sold.

UBS O'Connor first reported a position in BMRN in Q2 2013 and held it in 6 quarters. The position peaked at $2.62M in Q2 2013. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • UBS O'Connor reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 5,258 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $372K.
  • UBS O'Connor first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • UBS O'Connor's BioMarin Pharmaceuticals position peaked at $2.62M in Q2 2013.
  • 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.